Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL319903 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL3704062 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL18926545 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL12863969 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL16923810 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL10079611 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL562720 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22694307 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423269 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024089683-A1 | ANTICANCER DRUG CONJUGATES | Ariel Scientific Innovations Ltd. (IL) | 2024-05-02 | — | — | WO | disclosed |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA INC. | 2023-08-24 | — | — | US | disclosed |
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2022035818-A2 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PEPTINOVO BIOPHARMA, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3319980-B1 | FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS | PEPTINOVO BIOPHARMA LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | UNIV EMORY (US) | 2019-07-25 | — | — | US | disclosed |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | EMORY UNIVERSITY (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190076544-A1 | FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS | PEPTINOVO BIOPHARMA, LLC (US) | 2019-03-14 | — | — | US | disclosed |
| US-7550496-B2 | Compositions and methods for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| WO-2009018163-A1 | HYPOXIA ACTIVATED PRODRUGS OF ANTHRACYCLINES | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090017225-A1 | DELIVERY SYSTEMS FOR DELIVERING FUNCTIONAL COMPOUNDS TO SUBSTRATES AND PROCESSES OF USING THE SAME | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090017225-A1 | DELIVERY SYSTEMS FOR DELIVERING FUNCTIONAL COMPOUNDS TO SUBSTRATES AND PROCESSES OF USING THE SAME | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007920-A2 | DELIVERY SYSTEMS FOR DELIVERING FUNCTIONAL COMPOUNDS TO SUBSTRATES AND PROCESSES OF USING THE SAME | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-7442385-B2 | Chemoembolisation | BIOCOMPATIBLES UK LIMITED (GB) | 2008-10-28 | — | — | US | disclosed |
| WO-2008029310-A2 | DELIVERY SYSTEMS FOR DELIVERING FUNCTIONAL COMPOUNDS TO SUBSTRATES AND PROCESSES OF USING THE SAME | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-20080063718-A1 | Ultrasonics to energize alumina, silica, activated carbon, zeolite adsorbent; deliver pharmaceuticals, xenobiotics, therapeutic agents, nutritional agents, anti-viral agents, anti-microbial agents, UV absorbers, signal agents, to skin, body tissues; non-pharmaceutical compounds into consumer products | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080063718-A1 | Ultrasonics to energize alumina, silica, activated carbon, zeolite adsorbent; deliver pharmaceuticals, xenobiotics, therapeutic agents, nutritional agents, anti-viral agents, anti-microbial agents, UV absorbers, signal agents, to skin, body tissues; non-pharmaceutical compounds into consumer products | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-20060223812-A1 | Treating neurodegenerative conditions | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNGDER WISSENSCHAFTEN, E.V. (DE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223812-A1 | Treating neurodegenerative conditions | MAPT, HTT, PSEN2 | TOP2A 3596/4885MEN1 4383/4885THRB 4065/4885 |
| US-20190224378-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | TOP2A 410/4885MEN1 1227/4885THRB 197/4885 |
| US-20230265123-A1 | PEPTIDES AND FORMULATIONS FOR CANCER TREATMENT | PHOSPHO1, NGLY1, ANXA11 | TOP2A 3165/4885MEN1 226/4885THRB 2637/4885 |
| US-20190076544-A1 | FORMULATIONS FOR IMPROVING THE EFFICACY OF HYDROPHOBIC DRUGS | IAPP, CETP, ANXA6 | TOP2A 2518/4885MEN1 646/4885THRB 2593/4885 |
| US-20080063718-A1 | Ultrasonics to energize alumina, silica, activated carbon, zeolite adsorbent; deliver pharmaceuticals, xenobiotics, therapeutic agents, nutritional agents, anti-viral agents, anti-microbial agents, UV absorbers, signal agents, to skin, body tissues; non-pharmaceutical compounds into consumer products | FABP4, CUTA, FABP2 | TOP2A 4532/4885MEN1 2796/4885THRB 3992/4885 |
| US-20220054715-A1 | Bone Morphogenetic Protein Pathway Activation, Compositions for Ossification, and Methods Related Thereto | BMP4, SOST, BMP2 | TOP2A 410/4885MEN1 1227/4885THRB 197/4885 |
| US-11179501-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP4, SOST, BMP2 | TOP2A 410/4885MEN1 1227/4885THRB 197/4885 |
| US-10286113-B2 | Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto | BMP4, SOST, BMP2 | TOP2A 410/4885MEN1 1227/4885THRB 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.